Back to first-pass browser

First-pass extracted concept

idecabtagene vicleucel

Candidate: toolkit item2 source documents2 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

ide-cel

Extracted Explainers

What the tool is doing

Idecabtagene vicleucel is a BCMA-directed CAR-T cell product. The abstract states that it has FDA approval for relapsed/refractory multiple myeloma.

Source 1DOIPubMed

Idecabtagene vicleucel is named as an example of a BCMA-targeted CAR-T therapy in multiple myeloma. The review places it within a class that transformed outcomes in heavily pretreated refractory patients.

Source 2DOIPubMed

Resources required

Use requires the ide-cel CAR-T product and a BCMA-targeted treatment setting in relapsed/refractory multiple myeloma.

Source 1DOIPubMed

The abstract supports that it is a CAR-T cell therapy, but does not provide manufacturing or administration details.

Source 2DOIPubMed

What problem it solves

It provides an approved cellular immunotherapy option for relapsed/refractory multiple myeloma.

Source 1DOIPubMed

It is used for advanced refractory disease where better responses are needed.

Source 2DOIPubMed

What it does not solve

The abstract does not claim that ide-cel eliminates the broader tumor-, patient-, and product-related difficulties of CAR-T therapy.

Source 1DOIPubMed

The abstract does not specify how it compares with all other later-line options in every patient subgroup.

Source 2DOIPubMed

Alternatives

The abstract contrasts ide-cel with other BCMA-directed products such as cilta-cel and additional anti-BCMA medicines under development.

Source 1DOIPubMed

The review also names ciltacabtagene autoleucel and discusses anti-CD38 regimens, maintenance therapy, and future bispecific antibodies.

Source 2DOIPubMed

Evidence Snippets

Ide-cel ... [is a] CAR-T cell[] directed against BCMA, having received approval from the U.S. Food and Drug Administration for relapsed/refractory MM based on the phase 2 KarMMa ... trial[]
Evidence 1Source 1DOIPubMedprovenance
The emergence of B cell maturation antigen (BCMA)-targeted chimeric antigen receptor T (CAR-T) cell therapies, exemplified by idecabtagene vicleucel and ciltacabtagene autoleucel, has transformed outcomes in heavily pretreated, triple-class refractory patients, providing durable responses and quality of life benefits.
Evidence 2Source 2DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1approval statussupports2026Source 1DOIPubMed

Idecabtagene vicleucel is an FDA-approved BCMA-directed CAR-T therapy for relapsed/refractory multiple myeloma.

Claim 2review summarysupports2025Source 2DOIPubMed

BCMA-targeted CAR-T cell therapies such as idecabtagene vicleucel and ciltacabtagene autoleucel have transformed outcomes in heavily pretreated, triple-class refractory multiple myeloma and provide durable responses and quality-of-life benefits.